Lorianne Masuoka

Lorianne Masuoka

No open positions remaining
64 year
Health Technology
Consumer Services

Profile

Lorianne K.
Masuoka
worked as Senior Associate Director-Clinical Development at Bayer Schering Pharma AG and Berlex Laboratories, Inc. from 1994 to 2000.
From 2000 to 2003, served as Oncology Director at Chiron Corp.
Held the position of Vice President-Clinical Development at Five Prime Therapeutics, Inc. between 2003 and 2008.
Occupied the role of Chief Medical Officer & Senior Vice President at Nektar Therapeutics from 2009 to 2011.
Served as Chief Medical Officer at Cubist Pharmaceuticals LLC from 2013 to 2015, Invivo Therapeutics Holdings Corp.
from 2015 to 2017, Immedica Pharma US, Inc. from 2017 to 2019, Epygenix Therapeutics, Inc. from 2022 to 2023, and DiaMedica Therapeutics, Inc. from 2024 to 2025.
Held Independent Director roles at The Pelican, Inc. from 2019 to 2020 and Opiant Pharmaceuticals, Inc. from 2021 to 2023.
Education includes undergraduate and doctorate degrees from the University of California, Davis.

Former positions of Lorianne Masuoka

CompaniesPositionEnd
DIAMEDICA THERAPEUTICS INC. Chief Tech/Sci/R&D Officer 04/08/2025
Chief Tech/Sci/R&D Officer 01/12/2023
OPIANT PHARMACEUTICALS, INC. Director/Board Member 02/03/2023
PFENEX INC. Director/Board Member 01/10/2020
MARINUS PHARMACEUTICALS, INC. Chief Tech/Sci/R&D Officer 31/10/2019
See the detail of Lorianne Masuoka's experience

Training of Lorianne Masuoka

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

55

1st degree connections

13

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies13

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Consumer Services

Health Technology

Health Technology

Berlex Laboratories, Inc.

Health Technology

Health Technology

  1. Stock Market
  2. Insiders
  3. Lorianne Masuoka
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!